Top News
Novartis Has Production Hiccup for Kymriah CAR-T Therapy
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
FDA Reveals Biosimilar Plan; Gottlieb Blasts Delays
In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.
FDA Commissioner Gottlieb Releases Statement on Advancement of Gene Therapies
The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.
Takeda Receives US Clearance for $62-Billion Acquisition of Shire
The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.
Pfizer Announces Restructuring
Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products.
Biogen to Increase Stake in Samsung Bioepis Joint Venture for $700 Million
Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.
Novartis to Spinoff Alcon Eye Care Device Biz and Initiates $5-Billion Share Buyback
The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.
GE Spins Off Healthcare Unit as Stand-alone Business
Strategic restructuring is designed to position GE Healthcare as a pure-play healthcare company.
FDA Approves First Cannabidiol-based Drug
GW Research’s Epidiolex, which treats two forms of epilepsy, receives FDA’s approval; spurs FDA reminders about unapproved products.
Sanofi Completes $4.8-Billion Ablynx Acquisition
The acquisition is expected to strengthen Sanofi’s R&D strategy with Ablynx’s nanobody technology platform.
Roche to Acquire Foundation Medicine for $2.4 Billion
The acquisition is expected to strengthen Roche’s personalized healthcare strategy.
Bayer Completes Monsanto Acquisition for $63 Billion
Bayer completed its acquisition of Monsanto, the largest in Bayer’s history.
Bayer Gets US Approval for $66-Billion Acquisition of Monsanto
Bayer received conditional approval from the Antitrust Division of the United States Department of Justice to acquire Monsanto in a deal worth $66 billion.
Novartis Acquires AveXis for $8.7 Billion
The acquisition is expected to strengthen Novartis’ gene therapy pipeline.
Lilly to Acquire ARMO BioSciences for $1.6 Billion
Eli Lilly will acquire ARMO BioSciences to strengthen Lilly's immuno-oncology program.
Trump Drug Pricing Plan Outlines Rule Changes Pharma Can Live With
President Donald Trump announced his strategy for making prescription medicines more affordable and accessible in the United States.
J&J’s Janssen to Acquire BeneVir for $1 Billion
Johnson & Johnson’s Janssen Biotech will acquire biotechnology company BeneVir Biopharm to strengthen Janssen’s immunotherapy platform.
Takeda to Acquire Shire for $62 Billion
Takeda expands its global and therapy base with announced acquisition of Shire.
FDA Moves to Overhaul New Drug Review Process
Smaller review divisions will bring experts closer to decision processes and reduce bottlenecks, FDA leaders say.
Fresenius Terminates $4.3-Billion Merger with Akron
Fresenius Kabi claims that Akorn failed to fulfill several closing conditions.
Sanofi to Divest European Generics Business in Deal Worth $2.4 Billion
Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.
Merck KGaA to Sell Consumer Health Biz to Procter & Gamble for $4.2 Billion
The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.
Sanofi to Invest Roughly $430 Million in Canadian Vaccine Facility
The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.
Roche Completes $1.9-Billion Acquisition of Flatiron Health
The acquisition is expected to accelerate progress towards personalized cancer healthcare.
Boehringer Ingelheim and OSE in Immuno-Oncology Deal Worth $1.7 Billion
Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.
Fujifilm Expands Bioprocessing Scope
Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.
Takeda Confirms Interest in Acquiring Shire
Takeda is considering approaching Shire with a possible offer.
GSK Buys Out Novartis’ Share of OTC Business
In a $13-billion transaction, GSK will purchase Novartis’ share of the Consumer Healthcare Joint Venture.
Merck & Co., Eisai in Oncology Pact Worth Up to $5.76 Billion
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
Sanofi Acquires Biogen's Bioverativ
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
